TX-FLUENCE
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its collaboration with Westlandse Plantenkwekerij (WPK), a large Dutch propagator specializing in young plant cultivation for greenhouse horticulture in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005286/en/
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors. (Photo: Business Wire)
Originally founded in the 1930s by Arie van der Arend, WPK is a multi-generational family business now run by van der Arend’s descendants, Erik and Eviek. As a propagator, WPK oversees the seed-to-plant process for vegetable and tray plants for growers throughout Europe. The company’s scientific approach to cultivation has led to decades of success, ultimately driving WPK to enlist Fluence’s help to install research-backed LED lighting at their ’s-Gravenzande facility, jointly owned with Plantenkwekerij P. van Geest, for the very first time.
WPK introduced Fluence’s VYPR Series top lights alongside existing legacy high-pressure sodium (HPS) fixtures to harness the unique control a hybrid lighting approach offers for optimizing environmental factors—including controlling ambient heat. The hybrid lighting model at WPK’s facilities has led to better management of seasonal growing conditions and notable energy savings.
“After installing Fluence’s LED lighting solutions, we learned that young plants thrive in LED-lit environments,” said Erik van der Arend, managing director of WPK. “This has allowed us the flexibility to grow a wide range of crops in the same environment and under the same lighting conditions, decreasing hassle and improving our energy costs. The transition to Fluence has helped improve plant quality and speed of development, ensuring our customers get a uniform product that is consistently excellent.”
In collaboration with Fluence’s horticultural lighting experts, WPK fine-tuned the LEDs’ spectra to optimize operational costs while maintaining superior quality for the grower’s tomato, cucumber, pepper and flower crops. Early results show that WPK is realizing an estimated electricity savings between 40 and 50% by using two-thirds Fluence LED fixtures and one-third HPS in the greenhouse. Additionally, WPK increased total light levels by 30% due to the overall efficiency of LED technology. The post-installation harvests produced more compact, generative and vigorous plants that were darker or richer in color.
“The interesting thing about Fluence’s lighting technology is the right degree of cooling—the luminaire doesn’t get very hot,” van der Arend added. “Moreover, the spectrum is widely applicable.”
“When you work with Fluence, you’re not just buying a standalone LED light. You’re tapping into a network of leading lighting and horticultural experts who can help you create the right conditions to optimize your cultivation environment,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “That’s why we love working with propagators like WPK who share our passion for developing innovative lighting and environmental control strategies.”
For more information about the collaboration, visit here.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About WPK
Westlandse Plantenkwekerij (WPK) is a specialist in vegetable cultivation for professional greenhouse horticulture in Europe. WPK was established in the 1930s and currently has four cultivation facilities: two in 's-Gravenzande (South-Holland) and two in Made (North-Brabant). WPK makes the world a little greener with the cultivation of vegetable plants (such as tomato, pepper and cucumber), tray plants and potted flowering plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
